Phase 2 Pancreatic Cancer Trial, Recruiting NCT03492671 Sponsor: Loma Linda University Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Phase 2 Pancreatic Cancer Trial, Recruiting

NCT03492671
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been confirmed by a lab test (from a tissue or fluid sample) to have a type of pancreatic cancer called adenocarcinoma.
  • Your cancer is located only in the pancreas and may be removable by surgery.
  • You are 18 years of age or older.
  • You are generally healthy and able to carry out everyday activities with little to no limitation (confirm with trial site).
  • Your blood counts, kidney function, and liver function are within acceptable ranges as measured by blood tests (confirm with trial site).
  • You have never had any treatment for your pancreatic cancer before.
  • You do not currently have a serious infection that requires antibiotics given through a drip (IV).
  • You are not pregnant and not breastfeeding.

Who may not be able to join:

  • Your cancer is in a position that makes surgery uncertain or difficult, or the cancer has spread to other parts of the body.
  • You have been diagnosed with another type of cancer in the last 5 years, unless it was a very early-stage skin cancer, or a cancer that was fully treated and you have been cancer-free for at least 5 years.
  • You currently have an active bacterial, viral, or fungal infection that requires ongoing medical treatment.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Naveenraj Solomon, MD, Loma Linda University Cancer Center

Phone: 909-558-5498

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Loma Linda University
Registry
ClinicalTrials.gov
Start date
17 July 2019
Est. completion
1 September 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Curative Intent Resection (R0) rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov